Article

IPA Beers May Help Fight Cancer

Author(s):

Hops in beer contain antibacterial and anti-fungal properties, which could halt the growth of diseases.

In recent years beer has been touted for its health benefits — like increasing good cholesterol – but it’s the beer hops, the flowers of hops plants used to balance beer flavor by adding bitterness to the sweet maltiness, which may contain medicinal qualities.

Hops contain antibacterial and anti-fungal properties, which could halt the growth of diseases. The important hops compounds are humulones, which are alpha acids that have anticancer and anti-inflammatory properties, and lupulones, which are beta acids that have similar biological effects.

Before turning the compounds into effective pharmaceuticals, the scientists are working on channeling those anti-inflammatory and anticancer properties of beer hops and compare them to analytical standards before ultimately develop synthetic hops compounds in the lab.

Kristopher Waynant, PhD, and Lucas Sass, undergraduate student, University of Idaho, have been developing multi-step processes to synthesize three types of humulones.

According to Sass, “it’s been a lot of trial and error. But it’s so exciting when an approach finally works.”

Waynant will present their findings at the 251st National Meeting & Exposition of the American Chemical Society (ACS) in San Diego, CA.

Waynant remarked in a news release, “When researchers extract healthful chemicals from hops, they first have to determine whether they have separated out the specific compounds they’re interested in. But if you can figure out how to make these compounds from scratch, you know they are the right ones.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards